I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023
- Written by PR Newswire
![]() |
GAITHERSBURG, Md. and SHANGHAI, April 26, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that a poster featuring the latest clinical data of uliledlimab, the Company's proprietary and highly...
Read more: I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023















